[{"id":"578ed237-447e-411c-ac2e-ddd1c7129e54","acronym":"OATH","url":"https://clinicaltrials.gov/study/NCT04719273","created_at":"2024-03-13T13:34:11.049Z","updated_at":"2024-07-02T16:35:14.938Z","phase":"Phase 2","brief_title":"Onapristone and Anastrozole for the Treatment of Refractory Hormone Receptor Positive Endometrial Cancer","source_id_and_acronym":"NCT04719273 - OATH","lead_sponsor":"Thomas Jefferson University","biomarkers":" ER • PGR","pipe":" | ","alterations":" PGR expression","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e anastrozole • Apristor (onapristone XR)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 14","initiation":"Initiation: 01/28/2021","start_date":" 01/28/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-13"},{"id":"b4c10c17-3ade-414a-a83c-474c0b3bacd4","acronym":"","url":"https://clinicaltrials.gov/study/NCT04872608","created_at":"2021-05-04T11:52:45.021Z","updated_at":"2024-07-02T16:35:49.411Z","phase":"Phase 1b","brief_title":"A Study of Letrozole, Palbociclib, and Onapristone ER in People With Metastatic Breast Cancer","source_id_and_acronym":"NCT04872608","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 negative","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibrance (palbociclib) • letrozole • Apristor (onapristone XR)"],"overall_status":"Withdrawn","enrollment":"","initiation":"Initiation: 09/09/2021","start_date":" 09/09/2021","primary_txt":" Primary completion: 04/25/2023","primary_completion_date":" 04/25/2023","study_txt":" Completion: 04/25/2023","study_completion_date":" 04/25/2023","last_update_posted":"2023-04-28"},{"id":"068e98ca-b609-443c-b617-92e17feb845f","acronym":"ELONA","url":"https://clinicaltrials.gov/study/NCT05618613","created_at":"2022-11-16T18:56:49.734Z","updated_at":"2024-07-02T16:35:52.141Z","phase":"Phase 1b","brief_title":"Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer","source_id_and_acronym":"NCT05618613 - ELONA","lead_sponsor":"Context Therapeutics Inc.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Orserdu (elacestrant) • Apristor (onapristone XR)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 67","initiation":"Initiation: 12/02/2022","start_date":" 12/02/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2023-03-28"},{"id":"1e224f1e-e84d-4899-b75d-1b6cfb6c01ea","acronym":"ONAWA","url":"https://clinicaltrials.gov/study/NCT04142892","created_at":"2021-01-18T20:13:20.240Z","updated_at":"2024-07-02T16:36:14.253Z","phase":"Phase 1","brief_title":"Onapristone as Preoperative Treatment for Postmenopausal Women With Hormone Receptor + and HER2- Breast Cancer","source_id_and_acronym":"NCT04142892 - ONAWA","lead_sponsor":"SOLTI Breast Cancer Research Group","biomarkers":" HER-2 • ER • CD24 • ALDH1A1","pipe":" | ","alterations":" ER positive • HER-2 negative • CD44 expression • PGR expression","tags":["HER-2 • ER • CD24 • ALDH1A1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • CD44 expression • PGR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Apristor (onapristone XR)"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 11/06/2020","start_date":" 11/06/2020","primary_txt":" Primary completion: 04/30/2021","primary_completion_date":" 04/30/2021","study_txt":" Completion: 04/30/2021","study_completion_date":" 04/30/2021","last_update_posted":"2022-04-01"}]